MX346167B - Procedimientos para la preparacion de composiciones inyectables de liberacion controlada. - Google Patents

Procedimientos para la preparacion de composiciones inyectables de liberacion controlada.

Info

Publication number
MX346167B
MX346167B MX2012013867A MX2012013867A MX346167B MX 346167 B MX346167 B MX 346167B MX 2012013867 A MX2012013867 A MX 2012013867A MX 2012013867 A MX2012013867 A MX 2012013867A MX 346167 B MX346167 B MX 346167B
Authority
MX
Mexico
Prior art keywords
injectable depot
depot compositions
preparation
methods
lactic
Prior art date
Application number
MX2012013867A
Other languages
English (en)
Spanish (es)
Other versions
MX2012013867A (es
Inventor
Gutierro Aduriz Ibon
Teresa Gómez Ochoa María
Original Assignee
Laboratorios Farmacéuticos Rovi S A *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Farmacéuticos Rovi S A * filed Critical Laboratorios Farmacéuticos Rovi S A *
Publication of MX2012013867A publication Critical patent/MX2012013867A/es
Publication of MX346167B publication Critical patent/MX346167B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
MX2012013867A 2010-05-31 2011-05-31 Procedimientos para la preparacion de composiciones inyectables de liberacion controlada. MX346167B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10382153.4A EP2394663B1 (en) 2010-05-31 2010-05-31 Compositions for injectable in-situ biodegradable implants
PCT/EP2011/059001 WO2011151356A2 (en) 2010-05-31 2011-05-31 Methods for the preparation of injectable depot compositions

Publications (2)

Publication Number Publication Date
MX2012013867A MX2012013867A (es) 2013-01-24
MX346167B true MX346167B (es) 2017-03-08

Family

ID=43301929

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013867A MX346167B (es) 2010-05-31 2011-05-31 Procedimientos para la preparacion de composiciones inyectables de liberacion controlada.

Country Status (22)

Country Link
US (2) US10058504B2 (cg-RX-API-DMAC7.html)
EP (2) EP2394663B1 (cg-RX-API-DMAC7.html)
JP (1) JP5923493B2 (cg-RX-API-DMAC7.html)
CN (1) CN102933234A (cg-RX-API-DMAC7.html)
BR (1) BR112012030707A2 (cg-RX-API-DMAC7.html)
CA (1) CA2800641C (cg-RX-API-DMAC7.html)
CY (1) CY1124783T1 (cg-RX-API-DMAC7.html)
DK (1) DK2582395T3 (cg-RX-API-DMAC7.html)
EA (1) EA024211B1 (cg-RX-API-DMAC7.html)
ES (2) ES2897976T3 (cg-RX-API-DMAC7.html)
FI (1) FI2582395T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20211853T1 (cg-RX-API-DMAC7.html)
HU (3) HUE057236T2 (cg-RX-API-DMAC7.html)
LT (2) LT2394663T (cg-RX-API-DMAC7.html)
MX (1) MX346167B (cg-RX-API-DMAC7.html)
PL (2) PL2394663T3 (cg-RX-API-DMAC7.html)
PT (2) PT2394663T (cg-RX-API-DMAC7.html)
RS (2) RS64451B1 (cg-RX-API-DMAC7.html)
SI (2) SI2394663T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202100679T1 (cg-RX-API-DMAC7.html)
WO (1) WO2011151356A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201209394B (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US10010612B2 (en) 2007-05-25 2018-07-03 Indivior Uk Limited Sustained delivery formulations of risperidone compounds
ES2390439B1 (es) * 2012-08-03 2013-09-27 Laboratorios Farmacéuticos Rovi, S.A. Composición inyectable
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
HUE029895T2 (en) 2010-05-31 2017-04-28 Farm Rovi Lab Sa Antipsychotic injectable depot composition
LT2394663T (lt) 2010-05-31 2022-02-10 Laboratorios Farmaceuticos Rovi, S.A. Kompozicijos, skirtos įšvirkščiamiems in situ biologiškai skaidiems implantams
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
ES2456917T3 (es) * 2011-05-31 2014-04-24 Laboratorios Farmacéuticos Rovi, S.A. Formulación de implante de paliperidona
RS62059B1 (sr) * 2011-05-31 2021-07-30 Laboratorios Farmaceuticos Rovi S A Kompozicija implanta risperidona i/ili paliperidona
US8935726B2 (en) 2012-05-11 2015-01-13 Comcast Cable Communications, Llc Generation of dynamic content interfaces
HK1220628A1 (zh) 2013-03-11 2017-05-12 Durect Corporation 包含高粘度液体载体的可注射控制释放组合物
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
WO2017053346A1 (en) 2015-09-21 2017-03-30 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
CN113633609B (zh) * 2016-09-09 2023-08-04 中国疾病预防控制中心寄生虫病预防控制所(国家热带病研究中心) 抗寄生虫药物原位固化缓释注射剂及其制备方法
CA3037531A1 (en) * 2016-09-23 2018-03-29 Delpor, Inc. Compositions for small molecule therapeutic agent compounds
WO2018070940A1 (en) * 2016-10-14 2018-04-19 Nanyang Technological University An injectable composition for localized controlled and sustained delivery system
KR102615354B1 (ko) 2016-11-16 2023-12-21 페르시카 파마슈티컬스 리미티드 요통을 위한 항생제 제형
WO2018172850A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
RU2771279C2 (ru) * 2017-11-16 2022-04-29 Персика Фармасьютикалз Лтд. Композиции линезолида
PE20210047A1 (es) 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
WO2022153262A1 (en) 2021-01-18 2022-07-21 Anton Frenkel Pharmaceutical dosage form
CA3227324A1 (en) 2021-07-06 2023-01-12 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物
CN119072314A (zh) 2022-05-18 2024-12-03 罗维实验室制药股份公司 用于利培酮与cyp2d6酶抑制剂联合治疗的缓释注射组合物

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
BE758156R (fr) 1970-05-13 1971-04-28 Ethicon Inc Element de suture absorbable et sa
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4523591A (en) 1982-10-22 1985-06-18 Kaplan Donald S Polymers for injection molding of absorbable surgical devices
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5620700A (en) 1990-10-30 1997-04-15 Alza Corporation Injectable drug delivery system and method
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
KR100354270B1 (ko) 1993-11-19 2003-02-11 알커메스 컨트롤드 테라포이틱스 인코퍼레이티드 Ii 마이크로캡슐화된3-피페리디닐-치환된1,2-벤즈이속사졸및1,2-벤즈이소티아졸
US5620770A (en) 1995-06-01 1997-04-15 Superior Environmental Products, Inc. Fifth wheel insert, laminate composite and method of construction
DK0949905T3 (da) 1996-12-20 2001-10-22 Alza Corp Injicertbart depotelpræparat og fremgangsmåde til fremstilling
KR100289471B1 (ko) * 1998-01-19 2001-09-17 김충섭 휀타닐계마취제의이식형서방성제제
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
DE10190041D2 (de) * 2000-01-11 2002-12-05 Roland Bodmeier Implantate, Partikel
US6604561B2 (en) * 2000-02-11 2003-08-12 Medical Instill Technologies, Inc. Medicament vial having a heat-sealable cap, and apparatus and method for filling the vial
AU2002226000A1 (en) 2000-11-13 2002-05-21 Atrix Laboratories, Inc. Injectable sustained release delivery system with loperamide
US6565080B1 (en) 2001-12-17 2003-05-20 Hewlett-Packard Development Company, L.P. Imaging media loading guide
US7658998B2 (en) * 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
WO2004081196A2 (en) 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents
US20050003007A1 (en) 2003-07-02 2005-01-06 Michele Boix Method of sterilization of polymeric microparticles
EP1660039B1 (en) 2003-07-18 2016-09-28 Oakwood Laboratories L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
US8444600B2 (en) * 2003-09-17 2013-05-21 Jae Sang Park Replaceable heating cartridge for use with a warming device for medical treatment
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
EP1804751A2 (en) 2004-10-04 2007-07-11 QLT USA, Inc. Ocular delivery of polymeric delivery formulations
PT1824460E (pt) * 2004-11-10 2015-01-14 Tolmar Therapeutics Inc Um sistema de administração polimérico estabilizado
DE102005031868A1 (de) * 2005-07-04 2007-01-18 Biotronik Vi Patent Ag Arzneimitteldepot zur parenteralen, insbesondere intravaskulären Arzneimittelfreisetzung
US8852638B2 (en) * 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
SE0600876L (sv) * 2006-04-20 2007-10-21 Sandvik Intellectual Property Verktyg och skär för spånavskiljande bearbetning med primära och sekundära ingreppsmedel med rotationssymmetrisk form
US8076448B2 (en) 2006-10-11 2011-12-13 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
SI2079767T1 (sl) * 2006-10-11 2015-01-30 Tolmar Therapeutics, Inc. Priprava biorazgradljivih poliestrov, ki imajo lastnost majhnega izbruha, s superkritično tekočinsko ekstrakcijo
FR2908775B1 (fr) * 2006-11-17 2012-08-31 Biomatlante Hydrogel et ses applications biomedicales
PT2115029E (pt) 2007-02-15 2015-10-26 Tolmar Therapeutics Inc Poli-(lactido/glicolido) de efeito de libertação imediata reduzido e métodos de produção de polímeros
JP5009361B2 (ja) * 2007-03-29 2012-08-22 京セラ株式会社 携帯無線機
WO2008143992A2 (en) * 2007-05-18 2008-11-27 Durect Corporation Improved depot formulations
US10010612B2 (en) 2007-05-25 2018-07-03 Indivior Uk Limited Sustained delivery formulations of risperidone compounds
WO2009060473A2 (en) * 2007-11-06 2009-05-14 Panacea Biotec Limited Injectable compositions, processes and uses thereof
US8629172B2 (en) * 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
ES2390439B1 (es) 2012-08-03 2013-09-27 Laboratorios Farmacéuticos Rovi, S.A. Composición inyectable
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
HUE029895T2 (en) 2010-05-31 2017-04-28 Farm Rovi Lab Sa Antipsychotic injectable depot composition
LT2394663T (lt) 2010-05-31 2022-02-10 Laboratorios Farmaceuticos Rovi, S.A. Kompozicijos, skirtos įšvirkščiamiems in situ biologiškai skaidiems implantams
RS62059B1 (sr) 2011-05-31 2021-07-30 Laboratorios Farmaceuticos Rovi S A Kompozicija implanta risperidona i/ili paliperidona
ES2456917T3 (es) 2011-05-31 2014-04-24 Laboratorios Farmacéuticos Rovi, S.A. Formulación de implante de paliperidona

Also Published As

Publication number Publication date
EP2394663A1 (en) 2011-12-14
LT2394663T (lt) 2022-02-10
FI2582395T3 (fi) 2023-08-08
BR112012030707A2 (pt) 2016-11-01
US20180318208A1 (en) 2018-11-08
US10058504B2 (en) 2018-08-28
US20130177603A1 (en) 2013-07-11
CN102933234A (zh) 2013-02-13
ES2950857T3 (es) 2023-10-16
JP2013527213A (ja) 2013-06-27
PT2394663T (pt) 2021-11-26
US10195138B2 (en) 2019-02-05
LT2582395T (lt) 2023-08-10
RS64451B1 (sr) 2023-09-29
PT2582395T (pt) 2023-08-18
HRP20230890T1 (hr) 2023-11-10
DK2582395T3 (da) 2023-08-07
SI2394663T1 (sl) 2022-02-28
EA201201570A1 (ru) 2013-09-30
ES2897976T3 (es) 2022-03-03
SMT202300241T1 (it) 2023-09-06
CA2800641C (en) 2018-05-22
PL2394663T3 (pl) 2022-02-21
ZA201209394B (en) 2013-08-28
PL2582395T3 (pl) 2023-08-21
HUE063623T2 (hu) 2024-01-28
RS53205B (sr) 2014-06-30
EA024211B1 (ru) 2016-08-31
CY1124783T1 (el) 2022-11-25
SMT202100679T1 (it) 2022-01-10
HUE054922T2 (hu) 2021-10-28
MX2012013867A (es) 2013-01-24
SI2582395T1 (sl) 2023-10-30
EP2582395B1 (en) 2023-05-10
EP2582395A2 (en) 2013-04-24
HRP20211853T1 (hr) 2022-03-04
WO2011151356A2 (en) 2011-12-08
CA2800641A1 (en) 2011-12-08
HUE057236T2 (hu) 2022-04-28
WO2011151356A3 (en) 2012-03-22
JP5923493B2 (ja) 2016-05-24
EP2394663B1 (en) 2021-10-13

Similar Documents

Publication Publication Date Title
MX346167B (es) Procedimientos para la preparacion de composiciones inyectables de liberacion controlada.
UA111162C2 (uk) Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
PH12014502668A1 (en) Paliperidone implant formulation
EA201290497A1 (ru) Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых
IN2014DN02047A (cg-RX-API-DMAC7.html)
WO2011154724A3 (en) Injectable flowable composition comprising buprenorphine
NZ742800A (en) Modified alginates for anti-fibrotic materials and applications
MX338373B (es) Composicion antipsicotica inyectable de liberacion controlada.
IN2014DN10672A (cg-RX-API-DMAC7.html)
WO2012009661A3 (en) Conductive biopolymer implant for enhancing tissue repair and regeneration using electromagnetic fields
RU2010111357A (ru) Составы, содержащие клонидин в разлагаемом полимере
EP2395048A3 (en) Polymers compositions including an antioxidant
WO2015183920A3 (en) Methods and systems for converting precursor cells into gastric tissues through directed differentiation
WO2012027675A3 (en) Poly(beta-amino alcohols), their preparation, and uses thereof
EP4541385A3 (en) Adipose tissue products and methods of production
MX2014011815A (es) Composiciones farmaceuticas de liberacion inmediata con propiedades disuasivas de abuso.
IN2014CN00827A (cg-RX-API-DMAC7.html)
SA517381298B1 (ar) تركيبة صيدلية بثبات محسن
HK1208383A1 (en) Bioresorbable polymer peripheral scaffolds made from block copolymers of poly(l-lactide) and hydrophilic polymers
AU2018266690A1 (en) Biodegradable microparticles for sustained delivery of anti-angiogenic peptide
PH12012502093A1 (en) Composition for preventing or treating osteoporosis, and manufacturing method therefor
WO2010020972A8 (en) Implant device
RU2014104678A (ru) Имплантируемый стент
MX2021014775A (es) Composiciones de polimero de poliester monodisperso reabsorbible.
ZA202403104B (en) Pharmaceutical formulation comprising tacrolimus, method for the preparation thereof and use

Legal Events

Date Code Title Description
FG Grant or registration